Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Maekawa, Naoya ^a   Konnai, Satoru ^a   Okagawa, Tomohiro ^a   Nishimori, Asami ^a   Ikebuchi, Ryoyo ^a   Izumi, Yusuke ^a   Takagi, Satoshi ^a   Kagawa, Yumiko ^a,b   Nakajima, Chie ^c   Suzuki, Yasuhiko ^c   Kato, Yukinari ^d   Murata, Shiro ^a   Ohashi, Kazuhiko ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b North Lab   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR PROTEIN;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CONTROLLED STUDY; DOG DISEASE; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT NEOPLASTIC DISEASE; MASTOCYTOMA; MELANOMA; NONHUMAN; ORAL MELANOMA; OSTEOSARCOMA; PROSTATE ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; BIOSYNTHESIS; DOG; GENE EXPRESSION REGULATION; LYMPHOCYTE; METABOLISM; MOUTH TUMOR; PATHOLOGY; VETERINARY;

ANIMALS; ANTIGENS, CD274; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MALE; MELANOMA; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84975321792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157176     Document Type: Article

References (44)

1. Adams VJ, Evans KM, Sampson J, Wood JLN. Methods and mortality results of a health survey of purebred dogs in the UK. J Small Anim Pract. 2010; 51: 512-524. doi: 10.1111/j.1748-5827.2010.00974.x PMID: 21029096
2. Dobson JM, Samuel S, Milstein H, Rogers K, Wood JLN. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract. 2002; 43: 240-246. PMID: 12074288
3. Bronden LB, Nielsen SS, Toft N, Kristensen AT. Data from the Danish Veterinary Cancer Registry on the occurrence and distribution of neoplasms in dogs in Denmark. Vet Rec. 2010; 166: 586-590. doi: 10.1136/vr.b4808 PMID: 20453236
4. MacEwen EG, Patnaik AK, Harvey HJ, Hayes AA, Matus R. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest. 1986; 4: 397-402. PMID: 3801954
5. Wood CA, Moore AS, Gliatto JM, Ablin LA, Berg RJ, Rand WM. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). J Am Anim Hosp Assoc. 1998; 34: 417-421. PMID: 9728473
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med. 2012; 1-12.
7. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med. 2012; 1-11.
8. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol. 2008; 26: 677-704. doi: 10.1146/annurev.immunol.26.021607.090331 PMID: 18173375
9. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002; 793-800. PMID: 12091876
10. Sznol M, Chen L. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. Clin Cancer Res. 2013; 19: 1021-1034. doi: 10.1158/1078-0432.CCR-12-2063 PMID: 23460533
11. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006; 66: 3381-3385. PMID: 16585157
12. Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG, Xu N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem. 2006; 108: 19-24. PMID: 16530813
13. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006; 119: 317-327. PMID: 16482562
14. Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007; 19: 1223-34. PMID: 17898045
15. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of singleagent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28: 3167-3175. doi: 10.1200/JCO.2009.26.7609 PMID: 20516446
16. Maekawa N, Konnai S, Ikebuchi R, Okagawa T, Adachi M, Takagi S, et al. Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade. PLoS One. 2014; 9: e98415. doi: 10.1371/journal.pone.0098415 PMID: 24915569
17. Ikebuchi R, Konnai S, Okagawa T, Yokoyama K, Nakajima C, Suzuki Y, et al. Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes. Immunology. 2014; 142: 551-561. doi: 10.1111/imm.12243 PMID: 24405267
18. Esch KJ, Juelsgaard R, Martinez PA, Jones DE, Petersen CA. Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J Immunol. 2013; 191: 5542-5550. doi: 10.4049/jimmunol.1301810 PMID: 24154626
19. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984; 21: 469-474. PMID: 6435301
20. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol. 2002; 39: 651-678. PMID: 12450197
21. Murphy S, Hayes AM, Blackwood L, Maglennon G, Pattinson H, Sparkes AH. Oral malignant melanoma - the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol. 2005; 3: 222-229. doi: 10.1111/j.1476-5810.2005.00082.x PMID: 19754777
22. Spodnick GJ, Berg J, Rand WM, Schelling SH, Couto G, Harvey HJ, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc. 1992; 200: 995-9. PMID: 1577656
23. Szewczyk M, Lechowski R, Zabielska K. What do we know about canine osteosarcoma treatment?-review. Vet Res Commun. 2015; 39: 61-67. doi: 10.1007/s11259-014-9623-0 PMID: 25422073
24. Lussier DM, O'Neill L, Nieves LM, McAfee MS, Holechek SA, Collins AW, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother. 2015; 38: 96-106. doi: 10.1097/CJI.0000000000000065 PMID: 25751499
25. MacVean DW, Monlux AW, Anderson PS, Silberg SL, Roszel JF. Frequency of Canine and Feline Tumors in a Defined Population. Vet Pathol. 1978; 15: 700-715. PMID: 220774
26. Ogilvie GK, Powers BE, Mallinckrodt CH, Withrow SJ. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med. 1996; 10: 379-384. PMID: 8947871
27. Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, et al. Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas. PLoS One. 2013; 8: e82870. doi: 10.1371/journal.pone.0082870 PMID: 24349382
28. D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin L-X, Carvajal RD, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. Elsevier Inc.; 2015; 46: 357-65. doi: 10.1016/j.humpath.2014.11.001 PMID: 25540867
29. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation. 2002; 9: 133-45. PMID: 11932780
30. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 2003; 33: 3117-26. PMID: 14579280
31. Welle MM, Bley CR, Howard J, Rüfenacht S. Canine mast cell tumours: A review of the pathogenesis, clinical features, pathology and treatment. Vet Dermatol. 2008; 19: 321-339. doi: 10.1111/j.1365-3164.2008.00694.x PMID: 18980632
32. Bostock DE, Crocker J, Harris K, Smith P. Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours. Br J Cancer. 1989; 59: 915-8. PMID: 2500145
33. Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn Y-H, Byers LA, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5: 5241. doi: 10.1038/ncomms6241 PMID: 25348003
34. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, et al. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med. 2008; 22: 976-84. doi: 10.1111/j.1939-1676.2008.0133.x PMID: 18564221
35. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006; 8: 190-8. PMID: 16611412
36. Sorenmo KU, Goldschmidt MH, Shofer FS, Goldkamp C, Ferracone J. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol. 2004; 2: 13-23. doi: 10.1111/j.1476-5810.2004.00035.x PMID: 19379307
37. Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, et al. Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Target Oncol. 2015;[Epub ahead of print].
38. Taube JM, Klein AP, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 1: 5064-5075.
39. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007; 13: 84-8. PMID: 17159987
40. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2: 361-70. doi: 10.1158/2326-6066.CIR-13-0127 PMID: 24764583
41. Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol. 2002; 39: 458-72. PMID: 12126149
42. Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol. 2002; 39: 372-378. PMID: 12014501
43. Dickerson EB, Thomas R, Fosmire SP, Lamerato-Kozicki AR, Bianco SR, Wojcieszyn JW, et al. Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Vet Pathol. 2005; 42: 618-632. PMID: 16145208
44. Kanae Y, Endoh D, Yokota H, Taniyama H, Hayashi M. Tumor Suppressor Gene in Malignant Mammary Gland Tumors of Dogs. Am J Vet Res. 2006; 67: 127-133. PMID: 16426222